Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1629
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18552704 | MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18865881 | TRYPTAMINE DERIVATIVES | Non-Final OA | CAAMTECH, INC. |
| 18559492 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 18552718 | COMPOSITION FOR IMPROVING BLOOD CHOLESTEROL LEVEL | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18654312 | DOSAGE REGIMENS FOR PARP7 INHIBITORS | Final Rejection | Ribon Therapeutics, Inc. |
| 18371626 | DOSAGE REGIMENS FOR PARP7 INHIBITORS | Non-Final OA | Ribon Therapeutics, Inc. |
| 18266695 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | Non-Final OA | UNIVERZA V LJUBLJANI |
| 18630644 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | Non-Final OA | PHARMACYL AB |
| 17786949 | ORAL CANNABINOID FORMULATIONS | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18589498 | INFIGRATINIB FOR TREATMENT OF FGFR3-RELATED SKELETAL DISEASES DURING PREGNANCY | Non-Final OA | FONDATION IMAGINE |
| 18571039 | Crystalline Form of Sotorasib | Non-Final OA | Sandoz AG |
| 17679802 | Composition comprising at least one natural or synthetic non-euphoric cannabinoid and its method of manufacture | Final Rejection | Tilman |
| 18548342 | FPR2 (FORMYL PEPTIDE RECEPTOR 2)RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF THE AUTISM SPECTRUM DISORDER | Final Rejection | UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO |
| 18566887 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 18259843 | Methods of Treatment | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18018417 | METHOD FOR TREATING NEURODEGENERATIVE DISEASES BY ADMINISTERING BENFOTIAMINE OR DERIVATIVE THEREOF | Final Rejection | BURKE NEUROLOGICAL INSTITUTE |
| 18559542 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Non-Final OA | VORONOI INC. |
| 18559471 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | Non-Final OA | Saint Louis University |
| 18556100 | PHARMACEUTICAL COMPOSITION CONTAINING JAK3/JAK1/TBK1 SELECTIVE INHIBITOR AND MEDICAL USE THEREOF | Non-Final OA | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. |
| 18277851 | Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia | Non-Final OA | NEWAMSTERDAM PHARMA B.V. |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Final Rejection | Korea Institute of Science and Technology (KIST) |
| 17808476 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Final Rejection | YODA THERAPEUTICS INC. |
| 17049006 | DHA ENRICHED POLYUNSATURATED FATTY ACID COMPOSITIONS | Non-Final OA | Nuseed Nutritional US INC. |
| 17259296 | TOPICAL COMPSITION | Final Rejection | MC2 Therapeutics Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy